Cell- and gene-based therapies are being developed rapidly by numerous companies, including those operating in North Carolina. However, these companies face ongoing challenges including adequate product characterization, new safety risks, and the need for reliable and cost-effective manufacturing solutions. Currently, standardization of equipment, methods, and integrated automation are lagging for cell- and gene-based therapy product manufacturing. BPD is hosting a day-long virtual symposium to discuss these challenges and give attendees the opportunity to learn and network.
Sponsored by Aldevron, BPD's free symposium on April 22nd from 9 a.m. until 5 p.m. will include speakers from Pfizer, Biogen, Cellectis, KBI, and Precision Biosciences Inc.. Breaks between speakers will allow participants to visit virtual vendors, network, and participate in follow on discussions focused on topics presented by our speakers.
Virtual Exhibitors will include Beckman Coulter, Eppendorf NA, Watson Marlow, MaxCyte, Millipore Sigma, and IPS.
Time will be available from 1-2 p.m. to allow participants to attend Launch Bio's "Gene Therapy Thrives: Five Years of Growth in NC" free virtual panel without missing any BPD content. Registration for these two events are separate. “What makes North Carolina great for gene therapy? Experts from Sarepta, Novartis Gene Therapy, Beam Therapeutics, Audentes Therapeutics, and North Carolina Biotechnology Center will discuss the emergence of the state’s gene therapy ecosystem and share their predictions for the future of the industry.” Register for Launch Bio’s Webinar here.